Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues

Aditya Bagrodia, Christopher DiBlasio, Robert Wake, Ithaar Derweesh

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Prostate cancer (CaP) is the most common visceral malignancy and a leading cause of cancer death in men. Androgen deprivation therapy (ADT) is an established treatment for locally advanced and metastatic CaP, and often used as primary therapy in select patients. As ADT has continued to assume an important role in the treatment of CaP, a greater appreciation of potential adverse effects has been acknowledged in men receiving this therapy. Given that all treatments for CaP are frequently associated with some degree of morbidity and can have a negative impact on health-related quality of life (HRQOL), the potential benefits of any treatment, including ADT, must outweigh the risks, particularly in patients with asymptomatic disease. Once the choice to proceed with ADT is complete, it is imperative for the urologist to possess comprehensive knowledge of the potential adverse effects of ADT. This permits the urologist to properly monitor for, perhaps diminish, and to treat any linked morbidities. Patient complaints related to ADT such as a decrease in HRQOL, cognitive and sexual dysfunction, hot flashes, endocrine abnormalities, cardiovascular disease, and alterations in skeletal and body composition are commonly reported throughout the literature. Herein, we review the principal adverse effects linked with ADT in CaP patients and suggest various universal strategies that may diminish these potential adverse consequences associated with this therapy.

Original languageEnglish (US)
Pages (from-to)169-176
Number of pages8
JournalIndian Journal of Urology
Issue number2
StatePublished - Jul 1 2009


  • Androgen deprivation therapy
  • Complications
  • Prostate cancer

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues'. Together they form a unique fingerprint.

Cite this